Page last updated: 2024-11-08

hellebrigenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hellebrigenin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID259577
CHEMBL ID2068960
SCHEMBL ID13188019
MeSH IDM0041462

Synonyms (23)

Synonym
nsc-89594
bufotalidin
465-90-7
nsc89594
hellebrigenin
einecs 207-368-3
5-beta-bufa-20,22-dienolide, 3-beta,5,14-trihydroxy-19-oxo-
nsc 89594
bufa-20,22-dienolide, 3,5,14-trihydroxy-19-oxo-, (3beta,5beta)-
brn 0056259
19-oxo-3-beta,5,14-trihydroxy-5-beta-bufa-20,22-dienolide
C16969
(3s,5s,8r,9s,10s,13r,14s,17r)-3,5,14-trihydroxy-13-methyl-17-(6-oxopyran-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde
5-18-05-00180 (beilstein handbook reference)
CHEMBL2068960
SCHEMBL13188019
CS-0034272
HY-N6576
3,5,14-trihydroxy-19-oxobufa-20,22-dienolide
DTXSID90963594
bufa-20,22-dienolide,3,5,14-trihydroxy-19-oxo-,(3beta,5beta)-
MS-27249
AKOS040760445

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Measurements of the inotropic effects in guinea pig left atria performed at concentrations of acrihellin kept constant yielded a dose-response curve, which closely resembles that of the conventional cardioactive steroid ouabain."( Acrihellin, a cardioactive steroid escaping from the organ-bath.
Herzig, S; Lüllmann, H; Mohr, K; Seemann, B, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID155909Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/52002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1764996Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
AID1765003Inhibition of VEGFR2 mediated angiogenesis in transgenic Tg(flk1:GFP) zebra fish embryo at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
AID155910Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/52002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1765007Toxicity in zebra fish larvae assessed as pericardial edema at 100 uM measured at 48 hpf by stereomicroscopic analysis
AID1764999Induction of apoptosis in human SK-MEL cells assessed as increase in cleaved PARP level at 0.2 to 0.8 uM incubated for 48 hrs by Western blot analysis
AID1765001Antiangiogenic activity in transgenic Tg(fli1:GFP) zebra fish embryo assessed as reduction in intersegmental blood vessels at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
AID1765002Antiangiogenic activity in transgenic Tg(fli1:GFP) zebra fish embryo assessed as reduction in angiogenic sprouts at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's4 (44.44)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.46 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]